65 results
F-4
EX-10.15
MREO
Mereo Biopharma Group Plc
25 Jan 19
Registration of securities (foreign)
12:00am
health or disability (evidenced to the satisfaction of the Board);
b) redundancy (within the meaning of Part XI of the Employment Rights Act 1996;
c … in relation to an Option, and subject to the satisfaction (or waiver) of any conditions imposed pursuant to Rule 3.5, the crystallisation
S-8
EX-99.6
MREO
Mereo Biopharma Group Plc
15 Jan 21
Registration of securities for employees
4:21pm
where such cessation occurs for one of the following reasons:
a) injury, ill health or disability (evidenced to the satisfaction of the Board);
b … , other than as part of a scheme of reconstruction of the Company;
“Vest”
means in relation to an Option, and subject to the satisfaction (or waiver
F-4
EX-10.16
MREO
Mereo Biopharma Group Plc
25 Jan 19
Registration of securities (foreign)
12:00am
determines otherwise, the Vesting of Awards will be subject to the satisfaction of a Performance Condition, provided that an Award granted to an executive … director of the Company must be subject to the satisfaction of a Performance Condition. Subject to rules 11 and 12, the Performance Condition
S-8
EX-99.5
MREO
Mereo Biopharma Group Plc
15 Jan 21
Registration of securities for employees
4:21pm
.
PERFORMANCE CONDITION
Unless the Board determines otherwise, the Vesting of Awards will be subject to the satisfaction of a Performance Condition … , provided that an Award granted to an executive director of the Company must be subject to the satisfaction of a Performance Condition. Subject to rules 11
6-K
MREO
Mereo Biopharma Group Plc
20 Sep 23
Current report (foreign)
4:03pm
, if not resolved to its satisfaction, would have caused BDO LLP to make reference to the subject matter thereof in connection with its reports for such years
6-K
8uwg39968x
10 Feb 21
Mereo BioPharma Group plc Announces Proposed Public Offering of American Depositary Shares
5:23pm
6-K
EX-99.2
ibcln1
10 Feb 21
Mereo BioPharma Group plc Announces Proposed Public Offering of American Depositary Shares
5:23pm
6-K
EX-10.1
ymh robmhi
19 Feb 20
Mereo BioPharma Announces Equity Investment of $3 Million from New U.S. Institutional Investor
9:32am
6-K
EX-10.1
njqp9rdzb3sljd 59a
10 Feb 20
Current report (foreign)
7:20am
F-4
EX-10.1
9qi0c qiafw6
25 Jan 19
Registration of securities (foreign)
12:00am
POS AM
oy627sqr9ycuehj7
2 Jul 20
Prospectus update (post-effective amendment)
3:57pm
6-K
EX-99.1
j6o 72hzd50punqaed
17 Dec 20
Mereo BioPharma and Ultragenyx Announce Collaboration and License
5:16pm
6-K
EX-99.2
x1ihn8xs hnkv8hp
28 Oct 22
Mereo BioPharma Reaches Cooperation Agreement with Rubric Capital Management
7:11am
S-8
EX-99.1
cbr94 fdp
21 May 19
Registration of securities for employees
1:53pm
6-K
EX-10.4
w581lhz5fbnvjcp772
5 Jun 20
Mereo BioPharma Announces Completion of $70 Million Private Placement
12:00am
S-8
EX-99.1
1r7sv4u uw
15 Jan 21
Registration of securities for employees
4:21pm
S-8
EX-99.1
ll8 j28idsv
18 Feb 20
Registration of securities for employees
5:17pm
20-F
EX-4.7
irjui0y yw6p
29 Apr 19
Annual report (foreign)
4:59pm
425
8oi867j 6r3b
6 Dec 18
Business combination disclosure
2:26pm
F-4
EX-4.2
eyum47 khe3z70lv4s
25 Jan 19
Registration of securities (foreign)
12:00am